<DOC>
	<DOCNO>NCT00390403</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gossypol temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Gossypol may help temozolomide work well make tumor cell sensitive drug . Gossypol may also make tumor cell sensitive radiation therapy . Giving gossypol temozolomide together radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose gossypol give together temozolomide without radiation therapy treat patient newly diagnose glioblastoma multiforme .</brief_summary>
	<brief_title>Gossypol ( AT-101 ) Temozolomide With Without Radiation Therapy Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) gossypol ( AT-101 ) administer radiotherapy ( RT ) concurrent temozolomide ( TMZ ) patient newly diagnose glioblastoma multiforme . - Determine MTD gossypol administer adjuvant TMZ standard RT concurrent TMZ patient . Secondary - Assess toxicity treatment regimen . - Assess describe pharmacokinetics gossypol . - Determine , preliminarily , therapeutic activity regimens . - Determine relationship regimens cellular molecular feature identify tumor biopsy specimen . OUTLINE : This multicenter , open-label , nonrandomized , dose-escalation study gossypol . Patients assign 1 2 treatment group . Patients participate group I NOT eligible group II . - Group I : Patients receive oral gossypol undergo radiotherapy daily 5 day week 6 week . Patients also receive oral temozolomide daily 6 week . Treatment continue absence disease progression unacceptable toxicity . - Group II : Patients receive oral temozolomide day 1-5 oral gossypol daily day 1-21 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-10 patient per treatment group receive escalate dos gossypol maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 3 10 patient experience dose-limiting toxicity . Patients undergo blood collection periodically pharmacokinetic study . Tumor tissue sample examine biomarkers include , limited , Bcl-2 family protein expression ( e.g. , Bcl-2 , Bcl-xL , MCl-1 , Bax , Bak , BH3 domain ) , MGMT gene methylation status , gene expression array . After completion study treatment , patient follow every 2 month . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Gossypol acetic acid</mesh_term>
	<mesh_term>Retinol acetate</mesh_term>
	<mesh_term>Gossypol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm supratentorial grade IV astrocytoma ( glioblastoma multiforme ) Meets 1 follow criterion : Completed surgery within past 6 week ( group I ) Received radiotherapy concomitant temozolomide least 4 week 7 week prior start study treatment ( group II ) Must stable corticosteroid regimen ( increase 5 day ) PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Hemoglobin ≥ 10 g/dL Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤1.5 mg/dL Bilirubin ≤ 1.5 mg/dL ALT AST ≤ 2.5 time upper limit normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month completion study treatment Mini Mental State Exam score ≥ 15 Must able swallow retain oral medication No serious concurrent infection medical illness would preclude study participation No malignancy within past 5 year , except curatively treat carcinoma situ basal cell carcinoma skin No sensory neuropathy ≥ grade 2 No allergy gossypol No symptomatic hypercalcemia hypercalcemia &gt; grade 2 No gastrointestinal disease include follow : Malabsorption syndrome Disease significantly affect gastrointestinal function Ulcerative colitis Inflammatory bowel disease Partial complete small bowel obstruction PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered immediate postoperative period No prior radiotherapy , chemotherapy , immunotherapy , therapy biologic agent ( include immunotoxins , immunoconjugates , antisense agent , peptidereceptor antagonist , interferon , interleukin , tumorinfiltrating lymphocyte therapy , lymphokineactivated killer cell gene therapy ) , hormonal therapy brain tumor ( group I ) Prior glucocorticoid therapy allow No prior polifeprosan 20 carmustine implant ( Gliadel wafer ) ( group I ) No prior gossypol No prior radiosurgery brachytherapy No prior resection stomach small intestine No concurrent anticancer therapy ( i.e. , chemotherapeutics investigational agent ) No concurrent cytochrome p450 enzymeinducing anticonvulsant drug No concurrent prophylactic filgrastim ( GCSF ) No concurrent iron supplement Nutritional supplement contain iron allow No concurrent intensitymodulated radiotherapy No concurrent electron , particle , implant , stereotactic radiosurgery boost</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
</DOC>